Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): appendix b - proposal paper presented to the Institute's Guidance Executive
13 October 2014
(365.47 Kb 46 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 10 October 2014